Meridian Bioscience (VIVO) Receives FDA Emergency Use Authorization for Revogene SARS-CoV-2 Molecular Assay
Go back to Meridian Bioscience (VIVO) Receives FDA Emergency Use Authorization for Revogene SARS-CoV-2 Molecular Assay| Meridian Bioscience, Inc. (NASDAQ: VIVO) | Delayed: 5.66 -0.21 (3.58%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $5.87 | 52 Week High | $21.49 | |||
| Open | $5.52 | 52 Week Low | $15.75 | |||
| Day High | $6.04 | P/E | 6.43 | |||
| Day Low | $5.50 | EPS | $0.88 | |||
| Volume | 957,975 | |||||
